On July 11, 2016, in The Medicines Co. v. Hospira, Inc. (Case Nos. 2014-1469, -1504), the en banc Federal Circuit unanimously concluded that “to be ‘on sale’ under § 102(b), a product must be the subject of a commercial sale...more
On June 13, 2016, the U.S. Supreme Court ruled unanimously that “there is no precise rule or formula” for awarding enhanced patent damages under 35 U.S.C. § 284. Halo Electronics, Inc. v. Pulse Electronics, Inc., No. 14-1513,...more
6/14/2016
/ Enhanced Damages ,
Halo v Pulse ,
Patent Infringement ,
Popular ,
Preponderance of the Evidence ,
Remand ,
SCOTUS ,
Seagate ,
Stryker v Zimmer ,
Vacated ,
Willful Infringement